A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)
Oct 2026· Diabetes, obesity and metabolism· Vol 28, pp. 11955 - 11965· 0 citations· 18 references
Medicine
Abstract
To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).
Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al.· Journal of Diabetes· 0 citations
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.
L. Ji, Guo-Ping Yang, Yang-Qing Huang et al.· Diabetes, obesity and metabo...· 0 citations
Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D).
M. P. A. Baldassarre, G. Di Dalmazi, Federica Carrieri et al.· Diabetes, obesity and metabo...· 0 citations
Linaprazan glurate (LG), a potassium‐competitive acid blocker (PCAB), has shown up to 100% and 93% 4‐week healing rates in a Phase 2 study in patients with LA grade A/B and C/D erosive oesophagitis, respectively.
Crisugabalin (HSK16149), a selective γ‐aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown.
Ya-Ming Li, Fang Zhang, Wei Liu et al.· Diabetes, obesity and metabo...· 1 citation